

# **Tendon & Ligament Application of PRP**

*Sang Chul Lee, M.D, PhD.  
Department of Physical Medicine & Rehabilitation,  
Myongji hospital, Kwandong University College of Medicine*

# Tendon and Ligament

**Low metabolic rate at baseline**


**Predisposed to **slow** healing after injury**

**Platelet-Rich Plasma**

**PRP & Acute Injury**

**PRP & Chronic Injury**

**PRP & Rotator Cuff**



GF bind to **transmembrane receptors** on local or circulating cells  
 > **intracellular signaling**

> **production of proteins** responsible for cellular chemotaxis, matrix synthesis, and proliferation



# **Chronic Injury**

**Collagen fiber disruption**


**Muroid degeneration**

**Neovascularization**

**Absent or less inflammation**



Steroid  
NSAID



**TABLE 4.** Tendinopathy at the Elbow and Platelet-Rich Plasma: Results From a Randomized Controlled Study on Wrist Extensor Tendinopathy by Peerbooms et al<sup>41</sup> Using 1-mL Peppering Technique Injection and a Case–Control Study on Combined Group of Wrist Extensor Tendinopathy and Wrist Flexor Tendinopathy Patients by Mishra et al<sup>40</sup> Using 3-mL Peppering Technique Injection


	Baseline VAS	VAS Decrease				
		4 Weeks (%)	8 Weeks (%)	12 Weeks (%)	26 Weeks (%)	52 Weeks (%)
<u>PRP group (N = 51)<sup>41</sup></u>	70.1 (100%)	14.7 (21%)	23.2 (33.1%)	31.4 (44.8%)	37.5 (53%)	44.8 (63.9%)
<u>Control group (cortisone injection) (N = 49)<sup>41</sup></u>	65.8 (100%)	21.6 (32.8%)	22.9 (34.8%)	21.6 (32.8%)	9.2 (14%)	15.7 (24%)
PRP group (N = 15) <sup>40</sup>	80.3 (100%)	33.9 (46%)	48.3 (60%)	—	—	74.6 (93%)
Control group (bupivacaine injection) (N = 5) <sup>40</sup>	86 (100%)	15 (17%)	3 patients withdrew; 1 of 2 remaining patients showed nil symptoms	—	—	—

There were no reported significant between-group differences in pain scores in the study by Peerbooms et al, but there was a significant difference in the number of PRP-treated patients who achieved >25% reduction in visual analog pain scores at 1 year (primary outcome measure with a “pre-established analysis plan”).

**TABLE 4.** Tendinopathy at the Elbow and Platelet-Rich Plasma Tendinopathy by Peerbooms et al<sup>41</sup> Using 1-mL Peppering Wrist Extensor Tendinopathy and Wrist Flexor Tendinopathy

	Baseline VAS	4 Weeks (%)
<u>PRP group (N = 51)<sup>41</sup></u>	70.1 (100%)	14.7 (21%)
<u>Control group (cortisone injection) (N = 49)<sup>41</sup></u>	65.8 (100%)	21.6 (32.8%)
PRP group (N = 15) <sup>40</sup>	80.3 (100%)	33.9 (46%)
Control group (bupivacaine injection) (N = 5) <sup>40</sup>	86 (100%)	15 (17%)

There were no reported significant between-group differences in pain scores in patients who achieved >25% reduction in visual analog pain scores at 1 year (pr



**FIGURE 3** Brittberg-Peterson Pain VAS results.



# Properties of PRP

---

“Biological glue”

Coagulation and hemostasis

Wound healing

Provisional scaffold for stem or primary cell migration and differentiation

Intra-articular restoration of hyaluronic acid

Balances joint angiogenesis

Increases glycosaminoglycan chondrocyte synthesis and cartilage matrix

Anti-inflammatory

Antibacterial

Analgesic

---

TABLE 1  
Growth Factors Identified Within Platelet-Rich Plasma and Their Physiologic Effect<sup>a</sup>

Factor	Target Cell/Tissue	Function
PD-EGF	Blood vessel cells, outer skin cells Fibroblasts, and many other cell types	Cell growth, recruitment Differentiation, skin closure Cytokine secretion
PDGF A + B	Fibroblasts, smooth muscle cells, chondrocytes, osteoblasts, mesenchymal stem cells	Potent cell growth, recruitment <u>Blood vessel growth</u> , granulation Growth factor secretion; matrix formation with BMPs (collagen and bone)
TGF- $\beta$ 1	Blood vessel tissue, outer skin cells Fibroblasts, monocytes TGF gene family includes the BMPs Osteoblasts—highest levels of TGF- $\beta$ r	Blood vessel ( $\pm$ ), collagen synthesis Growth inhibition, apoptosis (cell death) Differentiation, activation
IGF-I, II	Bone, blood vessel, skin, other tissues Fibroblasts	Cell growth, differentiation, recruitment <u>Collagen synthesis</u> with PDGF
VEGF, ECGF	Blood vessel cells	Cell growth, migration, new blood vessel growth Anti-apoptosis (anti-cell death)
bFGF	Blood vessels, smooth muscle, skin Fibroblasts, other cell types	Cell growth Cell migration, blood vessel growth

<sup>a</sup>PD-EGF, platelet-derived epidermal growth factor; PDGF, platelet-derived growth factor; BMP, bone morphogenetic protein; TGF, transforming growth factor; IGF, insulin-like growth factor; VEGF, vascular endothelial growth factor; ECGF, endothelial cell growth factor; bFGF, basic fibroblast growth factor.

# Platelet-Rich Plasma

**GFs: “normal” biologic ratios**

Increased **cell numbers** with increasing PRP concentration from **1% to 10%**, Plateau in the **dose–response** effect

**Non-growth factors** in the **dense granules**

Tendon **collagen** in vivo activate PRP



In vitro, rabbit patellar tendon,

PRP treated tendon **stem/progenitor cell** differentiate into **tenocyte**

# Platelet-Rich Plasma

To **synergistically assist** inflammatory cascade and healing injured tissue by **manipulating** GFs and bioactive proteins

To create a provisional **fibrin scaffold**



# Wound healing:

## Repair of Collapsed Building

Platelet: relatively **passively** involved

**GF**: just the **messenger**/ not giving the orders

Macrophage: tissue repair **brain**

Fibroblast, satellite cell: actual **builder**

Fibroblast: produce **collagen** infrastructure

satellite cell: form **tenocyte**, etc



# PRP need to be determined

Volume of injection/application

Buffering/activation (**lidocaine?**)

**Timing** of injection to injury

**Single** vs **Serial** injections

Injection technique (**one** vs **multiple**)

Most effective **rehabilitation** protocol

# Remodelling Phase

Collagen is reorganized and stabilized  
by also **GH** mediation

Tissue is remodeled through **normal physiologic turnover** in response to loading, stress, and humoral factors

The most important external stimulus is enhancing **mechanobiological signaling** by means of **rehabilitation** and physical therapy

# How can one platelet injection after tendon injury lead to a stronger tendon after 4 weeks?

Interplay between early regeneration and mechanical stimulation

Olena Virchenko and Per Aspenberg

At 14 days, unloading (with Botox) abolished any effect of PRP to less than half of normal

**Mechanical stimulation** is a prerequisite for the effect of PRP





# Acute Injury



# Acute Tendon and Ligament Injury

Potential to exacerbate inflammation (**pain**)  
in the setting of acute injury

However,

Often **slow** to heal and are prone to **reinjury**

To promote an increase in healing, level of  
at least **1,000,000/mL** is needed

# Acute Tendon and Ligament Injury

PRP may be even **more effective** for acute injuries than chronic injury

Greatest effect: early PRP within **24** hours

# Acute Tendon and Ligament Injury

## Equine FDS tendon explants cultured in PRP


gene expression of type I collagen, type III collagen,  
cartilage oligomeric **matrix protein** ↑

## In vivo, injection, 6 hours after creation of defect in a rat Achilles tendon

**tendon callus strength** and stiffness ↑

## PRP injected into patellar tendon injury in a chimeric rat

recruitment of circulation-derived cells to the injury site ↑  
**collagen production** ↑



## Medial collateral ligament injuries of the knee

PRP vs **Rest & Rehabilitation**

Professional soccer players with grade 2 acute medial collateral ligament injuries (n=22)

PRP injections: within 72 hours of injury

**Return-to-play time:**

Shortened by **27%** compared to the control group

# Ankle Injury

**Calcium**-activated PRP

For type 3 ankle syndesmotic injuries in 11 patients

Average time of healing  
**5.18** weeks vs 8.00 weeks


**Syndesmosis Injury**



# Anterior Cruciate Ligament

**Grafts** With and Without PRP


**Mean time** to obtain a completely PRP group needed only **48%** of time control group required to achieve **homogeneous** intra-articular segment on MRI image



# Anterior Cruciate Ligament

Human **RCTs** have **failed** to show effect

PRP application **cannot be recommended** in combination with ACL reconstruction





# Achilles Tendon Rupture

In case-controlled study of **Surgical repair**

Significant improvement in the **PRP adjunctive** group for  
earlier ankle ROM,  
early return to gentle running  
to sports training  
decreased tendon CSA

Small patient group numbers (**n = 6**)



# Achilles tendon rupture

RCT: 30 patients


OP + PRP 10cc

At 1-year follow-up,

No significant difference in heel raise index

**However,** Achilles tendon Total Rupture Score was significantly **lower** in the PRP group

# Chronic Injury



# Chronic Tendon Injury

With chronic injuries, particularly **tendon** injuries

with **no, or minimal**, inflammatory component, the rationale for PRP, is **less clear**

**A traumatic model** was used in the equine study, and the effects of PRP might be different in **degenerative** tendon tissue

**Absence** of basic science studies on growth factors and PRP in **chronic tendon injury models**

# Chronic Tendon Injury

Process of wound repair may be inhibited due to

**Compromised vascularity**

**Limited cellularity**

Paucity of platelets and **decrease in healing potential**

To stimulate the tissue and **restart** the inflammatory process,

Making the chronic injury into a **new acute injury!**

# **General Management**

## **Chronic Tendon Injury**

### **Eccentric exercises**

Promote collagen fiber **cross-link formation**  
within the tendon

> facilitating **tendon remodeling**

# Steroid: still debated

## Lateral Epicondylitis

Corticosteroid **injection**  
reduced pain in the **short** term

**worse** in the **long** term than are  
most conservative interventions

**Repeated** corticosteroid  
injections (average of 4.3, 18  
months) were associated with a  
**poorer** long-term effect on  
reduction in pain than one  
injection

## Rotator cuff tendinopathy

Short-term efficacy: **not  
clear**, inconsistent

Of the 416

38 (9%) cases of atrophy

31 (8%) cases of pain

2 (<1%) cases of  
depigmentation

1 (<1%) case of tendon  
rupture of the Achilles  
tendon

10 studies in animals :

damage to tendons: **not  
established**

# **Extracorporeal Shock Wave Therapy**

**Mechanical forces** generated directly or indirectly via cavitations

**Stimulation of soft-tissue healing**

**inhibition of pain receptors**

**ESWT or Eccentric training** for Achilles tendinopathy

**Comparable results in a RCT**



# Extracorporeal shock-wave therapy for tendinitis of rotator cuff

Speed CA et al  
JBJS Br 2002

- Double-blind, randomized, controlled trial, n=74
- Painful arc, impingement sign
- Shoulder pain & disability Index (SPADI)

Table II. The number and *percentage* of subjects with improvement of 50% from baseline at three months

	Group ESWT	Sham	p value	Odds ratio	95% confidence interval
SPADI	12 (35.0)	18 (45.0)	0.479	1.176	0.809 to 0.711
Subscales					
Pain	15 (44.0)	13 (38.0)	0.8180	0.8726	0.3482 to 2.186
Disability	19 (47.5)	14 (35.0)	0.8122	1.150	0.4450 to 2.970
Night pain	14 (41.0)	15 (37.5)	0.814	0.941	0.650 to 1.362

- Significant placebo effect, but no evidence of benefit compare to sham Tx.
- Do not recommend ESWT for the Tx of SS tendinitis!

# Operative Treatment

To **excise** fibrotic adhesions

To remove or **debride** areas of failed healing

To restore **vascularity**, and possibly **stimulate viable cells** to initiate protein synthesis and to promote healing

To destruct **neovessels**

# US-guided microtenotomy

Achilles tendon, Tennis elbow

Ablation of **sensory nerve fibers**

**Needling** within the tendon improved **tendon structure**

**PRP**; to stimulate angiogenesis and remodeling by  
tenocytes                      **Synergy Effect?**

**Platelet-Rich Plasma : From Basic  
Science to Clinical Applications**  
*Am J Sports Med* 2009  
Timothy E. et al.

**Empirical PRP Use**

# Achilles Tendinopathy

Conventional conservative therapy : ineffective in around 25%

**US** guidance for needle **localization** and **confirmation** of the PRP directly into the affected area

Immediately after the injection, **protection with a brace** and **removal from athletic activity**

Immediate protocol of active and active-assisted ROM strictly in the PF–DF plane

Gradually progresses with a standard protocol for strength and functional recovery

Gradual return to activities over 6 to 8 weeks

# Achilles Tendinopathy

De Vos RJ, compared with **saline inj**:


Injecting PRP for treatment of chronic midportion Achilles tendinopathy  
(one injection, three puncture, **five small depots**)

**does not**

contribute to an increased tendon structure

Alter degree of neovascularisation, compared with **placebo**

Eccentric exercise program **overshadowed** an effect of PRP



**(A)Initial, (B) reparative process , (C) final follow-up at 3 months**

**MRIs: lesion with disruption of the signal within the tendon and widening of the tendon edges**

# Plantar Fasciitis

Chronic **refractory** plantar fasciitis

Injection into **medial** plantar fascia with **ultrasound** guidance

Post-injection protocol: **immediate** Wt. bearing, standard **rehabilitation** program for strength and functional progress

Beneficial for patients with **tears** of the plantar fascia:  
**no data**



# Plantar Fasciitis

Barrett and Erredge, 2004

Calcium activated PRP in liquid form  
for injection

**6/9** patients achieved complete  
symptomatic relief after **2 months**  
**1/3** unsuccessful patients eventually  
achieved complete resolution of  
symptoms after **2<sup>nd</sup> PRP** injection  
Overall, **77.9%** complete resolution  
symptoms at **1yr**



# Patellar Tendinopathy

PRP treatment for patellar tendinosis are as follows:

- 1) severe symptoms present for more than **3 months unresponsive** to physical therapy
- 2) confirmed by US or MRI
- 3) “washout” period from NSAIDs for at least 1 week before PRP injection

Avoid NSAID use for 3 to 4 weeks after intervention

The postinjection protocol: same

**Ice**, particularly in the early stages, helpful in controlling post injection pain

# Patellar Tendinopathy

5-mL PRP injections separated by 15 days

3-injection treatment, at the 6-month follow-up

(SF-36 and EQ-VAS; N = 20)

**Significant improvement** in pain and physical function using health QOL scales

Other study (n=31)

PRP +rehabilitation protocol vs rehabilitation protocol

**No** between-group difference in VAS score

# Rotator cuff with PRP

**Intrinsic factor: age-related degeneration**

**Extrinsic factor: Hooked acromion, Repetitive microtrauma**

**Postoperative rotator cuff retears : 11 to 94%**



# Rotator cuff with PRP

The area of injury: identified and clearly marked based on physical examination, imaging studies, and area of maximal tenderness

Dynamic musculoskeletal **US**: for the accurate placement of PRP into the pathologic region of tendon

A **multiplanar injection technique** (peppering the tendon): to deliver the platelets to a **wider surface** area thus potentially enhance the healing process

**Acetaminophen** with or without **narcotic** medication

For post-injection pain

**NSAIDs**: not be used in the first 2 weeks after injection



**Neer's Test For Impingement   Hawkins Test For Impingement**



**Supraspinatus (Empty Can) Test**





**Testing Infraspinatus And Teres Minor (External Rotators)**

**Gerbers Lutoff Test (Subscapularis)**





**Figure 29:** Passive horizontal lateral rotation.



# Rotator cuff with PRP

**Small and medium** rotator cuff tears  
arthroscopic rotator cuff repair without (n = 45) or with (n = 43) PRP  
follow-up at **16 months**

**No** statistically significant difference in total Constant score & MRI  
Operated shoulder: **immobilized** for 3 weeks using a sling

Significantly **fewer narcotics** for less than half the time of counterparts

In **massive** rotator cuff surgery: **good results** adding PRP gel

**SLAP**: shown to accelerate **healing** and reduce **pain** as compared with controls

**Does the PRP **remain** within the tendon or muscle injected?**

**How important is **tenotomy (needling)** in conjunction with PRP?**

**Current study is purposed to verify the effect of PRP **itself** and to reveal the **synergic** effect of PRP with dry needling**

Only **supraspinatus** with rotator cuff lesion confirmed by US

Included Tendinosis or Partial tear

SASD Bursitis -excluded

Dry needling vs PRP+dry needling

Two 3-mL PRP injections separated by 1 month


At the 6-month follow-up

Result: not yet...


# Interaction Between the Supraspinatus and Infraspinatus Tendons : Effect of Anterior Supraspinatus Tendon Full-Thickness Tears on Infraspinatus Tendon Strain

Nelly Andarawis-Puri, Eric T. Ricchetti and Louis J. Soslowsky

*Am J Sports Med* 2009 37: 1831 originally published online May 29, 2009



**fresh-frozen cadaveric shoulders**



**Conventional Tx is not enough**

**Proceeding to Next step**

**PRP can not take the place of**

**Rehab!**



**Thank you for listening^^**